Aegis Capital Comments on Amarin (AMRN) Following Q2 Results, Commercialization Update
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/21/2026
- Wall St indexes advance with boost from chips, Iran optimism
- Intel soars after Trump says Apple agreed to work with chipmaker on US production
- Apple CEO warns price hikes 'unavoidable' as chip costs bite - WSJ
- Wall Street scrambles to lift Micron price targets ahead of earnings
- SanDisk and Micron surge as Apple confirms memory price pass-through
- Zelenskiy: best guarantee of Europe's future is fast-track EU membership for Ukraine
- Needham Starts NeoVolta (NEOV) at Buy
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Companies to add 40 million barrels of oil to US SPR after Iran war ends, energy secretary says
- Tesla acquires AI hardware company for up to $2 billion in stock
Amarin (AMRN): Goldman Remains Neutral as Investors Await FDA Response on ANCHOR Appeal
August 8, 2014 1:05 PM EDTGoldman Sachs maintained a Neutral rating on Amarin Corporation (NASDAQ: AMRN) with a price target of $1.90. Comments follow Q2 results. Analyst Gary Nachman said he was awaiting FDA response on its ANCHOR appeal.
"The Vascepa co-promote with Kowa began in mid-May and we have started to see a positive impact on Rxs, but it is... More
Amarin Corp plc (AMRN) Tops Q2 EPS by 1c
August 7, 2014 4:24 PM EDTAmarin Corp plc (NASDAQ: AMRN) reported Q2 EPS of ($0.14), $0.01 better than the analyst estimate of ($0.15). Revenue for the quarter came in at $12.6 million versus the consensus estimate of $12.86 million.
Amarin reported cash and cash equivalents of $150.5 million at June 30, 2014, representing a net decrease of $13.8 million from reported cash and cash equivalents of $164.3 million as of March 31, 2014... More
Amarin Corp plc (AMRN) Files $300M Mixed Securities Shelf
August 7, 2014 4:22 PM EDTAmarin Corp plc (NASDAQ: AMRN) filed a $300 million mixed securities shelf on form S-3.
... More